Genocea Biosciences (GNCA) : During the past 4 weeks, traders have been relatively bearish on Genocea Biosciences (GNCA), hence the stock is down -4.14% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.89% relative to the S&P 500. The 4-week change in the price of the stock is -4.66% and the stock has fallen -6.74% in the past 1 week.
The stock has recorded a 20-day Moving Average of 6.84% and the 50-Day Moving Average is 1.42%.The 200 Day SMA reached 11.73%
Genocea Biosciences (NASDAQ:GNCA): After opening at $5.13, the stock dipped to an intraday low of $5.02 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $5.39 and the buying power remained strong till the end. The stock closed at $5.12 for the day, a gain of 1.19% for the day session. The total traded volume was 839,367. The stocks close on the previous trading day was $5.12.
Genocea Biosciences (GNCA) : Currently there are 5 street experts covering Genocea Biosciences (GNCA) stock. The most bullish and bearish price target for the stock is $40 and $9 respectively for the short term. The average price target of all the analysts comes to $18.8. The estimated standard deviation from the target is $12.22.
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies to address diseases with unmet needs. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria. It also creates a library of every protein in the proteome of the pathogen of interest. It uses ATLAS as a throughput engine to screen human T cells to identify relevant T cell vaccine antigens.